Literature DB >> 199944

Coagulation abnormalities in liver disease.

K Lechner, H Niessner, E Thaler.   

Abstract

The decreased capacity of the liver to synthesize proteins is the main cause of decreased blood levels of clotting factors II, V, VII, IX, X and of antithrombin III in patients with liver disease. Therefore, determination of the activity or concentration of these coagulation proteins is a useful test of liver function and guide to prognosis, provided that other mechanisms which may influence the blood level are carefully considered. Clotting factor assays have an only limited value for the differential diagnosis in liver disease.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 199944     DOI： 10.1055/s-0028-1087127

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN： 0094-6176            Impact factor:   4.180


  8 in total

1.  Predictors and noninvasive identification of severe liver fibrosis in patients with chronic hepatitis C.

Authors:  Mohamed A Metwally; Claudia O Zein; Nizar N Zein
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

Review 2.  New insights into the coagulopathy of liver disease and liver transplantation.

Authors:  M Senzolo; P Burra; E Cholongitas; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

3.  The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease.

Authors:  R Scherer; M Kabatnik; J Erhard; J Peters
Journal:  Intensive Care Med       Date:  1997-11       Impact factor: 17.440

4.  Haemostatic alterations in malaria correlate to parasitaemia.

Authors:  R D Horstmann; M Dietrich
Journal:  Blut       Date:  1985-11

5.  Biosynthesis of coagulation Factor V by a human hepatocellular carcinoma cell line.

Authors:  D B Wilson; H H Salem; J S Mruk; I Maruyama; P W Majerus
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

Review 6.  Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.

Authors:  R Michael Grounds; Charles Bolan
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

7.  Platelet IgG antibodies are significantly increased in chronic liver disease.

Authors:  Dimitrios Christodoulou; Konstantinos Katsanos; Eleftheria Zervou; Vasileios Theopistos; Athanasios Papathanasopoulos; Leonidas Christou; Epameinondas V Tsianos
Journal:  Ann Gastroenterol       Date:  2011

Review 8.  Cirrhosis and Coagulopathy: Mechanisms of Hemostasis Changes in Liver Failure and Their Management.

Authors:  Rabia Islam; Sumana Kundu; Surajkumar B Jha; Ana P Rivera; Gabriela Vanessa Flores Monar; Hamza Islam; Sri Madhurima Puttagunta; Ibrahim Sange
Journal:  Cureus       Date:  2022-04-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.